4.7 Article

Immune Responses to HBV Vaccine in People Living with HIV (PLWHs) Who Achieved Successful Treatment: A Prospective Cohort Study

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Health Care Sciences & Services

Could Long-Acting Cabotegravir-Rilpivirine Be the Future for All People Living with HIV? Response Based on Genotype Resistance Test from a Multicenter Italian Cohort

Andrea De Vito et al.

Summary: This study aimed to estimate the patients eligible for the new LA therapy with cabotegravir (CAB) + rilpivirine (RPV) for HIV. According to the snapshot, roughly 39.9% of virologically suppressed patients may be suitable candidates for long-acting CAB+RPV therapy. Therefore, individual characteristics should be taken into consideration when tailoring antiretroviral treatment.

JOURNAL OF PERSONALIZED MEDICINE (2022)

Article Immunology

Immune Response to Hepatitis B Virus Vaccine Among People Living With HIV: A Meta-Analysis

Yakun Tian et al.

Summary: A meta-analysis study found that a double dose and multiple injections of the HBV vaccine were more effective in inducing immune responses in people living with HIV compared to the standard dose. Participants with higher CD4+ T-cell levels showed better vaccine response rates, highlighting the importance of timely HBV vaccination in individuals infected with HIV.

FRONTIERS IN IMMUNOLOGY (2021)

Article Immunology

Naive CD4+ cell counts significantly decay and high HIV RNA levels contribute to immunological progression in long-term non-progressors infected with HIV by blood products: a cohort study

Ling Xu et al.

Summary: In long-term non-progressors infected with HIV through blood products, the main characteristic of immunological progression was the decrease of naive CD4(+) T cells, which may be associated with high HIV RNA levels.

BMC IMMUNOLOGY (2021)

Article Infectious Diseases

Therapeutic prediction of HIV-1 DNA decay: a multicenter longitudinal cohort study

Yongsong Yue et al.

Summary: Baseline total HIV-1 DNA and CD4+ T cell count are two independent predictors of total HIV-1 DNA after treatment. The derived model based on these two baseline factors provides a useful prognostic tool in predicting HIV-1 DNA reservoir control during cART.

BMC INFECTIOUS DISEASES (2021)

Review Immunology

Shared immunotherapeutic approaches in HIV and hepatitis B virus: combine and conquer

Mala K. Maini et al.

CURRENT OPINION IN HIV AND AIDS (2020)

Article Immunology

Long-Term TDF-Inclusive ART and Progressive Rates of HBsAg Loss in HIV-HBV Coinfection-Lessons for Functional HBV Cure?

Jennifer Audsley et al.

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2020)

Article Infectious Diseases

Hepatitis B Vaccination and Waning Hepatitis B Immunity in Persons Living with HIV

Priya D. Farooq et al.

CURRENT HIV/AIDS REPORTS (2019)

Review Microbiology

Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications

Veronique Avettand-Fenoel et al.

CLINICAL MICROBIOLOGY REVIEWS (2016)

Article Public, Environmental & Occupational Health

Response to anti-HBV vaccine and 10-year follow-up of antibody levels in healthcare workers

V. La Fauci et al.

PUBLIC HEALTH (2016)